Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging.

Howes OD, Egerton A, Allan V, McGuire P, Stokes P, Kapur S.

Curr Pharm Des. 2009;15(22):2550-9. Review.

2.

Atypical antipsychotics: mechanism of action.

Seeman P.

Can J Psychiatry. 2002 Feb;47(1):27-38. Review.

PMID:
11873706
3.

Antipsychotic efficacy: relationship to optimal D2-receptor occupancy.

Pani L, Pira L, Marchese G.

Eur Psychiatry. 2007 Jul;22(5):267-75. Epub 2007 Apr 6. Review.

PMID:
17419008
4.
5.

[Theory in antipsychotic drug therapy for schizophrenia].

Tomioka S, Ishigooka J.

Seishin Shinkeigaku Zasshi. 2006;108(6):614-8. Review. Japanese.

PMID:
16910539
6.

Recent developments in PET scan imaging of neuroreceptors in schizophrenia.

Sedvall G, Pauli S, Farde L, Karlsson P, Nyberg S, Nordström AL.

Isr J Psychiatry Relat Sci. 1995;32(1):22-9. Review.

PMID:
7622344
7.

Probing targets for antipsychotic drug action with PET and SPET receptor imaging.

Pilowsky LS.

Nucl Med Commun. 2001 Jul;22(7):829-33. Review.

PMID:
11453058
8.

Estimating dopamine D₂ receptor occupancy for doses of 8 antipsychotics: a meta-analysis.

Lako IM, van den Heuvel ER, Knegtering H, Bruggeman R, Taxis K.

J Clin Psychopharmacol. 2013 Oct;33(5):675-81. doi: 10.1097/JCP.0b013e3182983ffa. Review.

PMID:
23948784
9.

Antipsychotic occupancy of dopamine receptors in schizophrenia.

Nord M, Farde L.

CNS Neurosci Ther. 2011 Apr;17(2):97-103. doi: 10.1111/j.1755-5949.2010.00222.x. Epub 2010 Dec 8. Review.

PMID:
21143431
10.

[The next generation of "atypical" antipsychotics: the role of positron emission tomography].

Gründer G, Wong DF.

Fortschr Neurol Psychiatr. 2003 Aug;71(8):415-20. Review. German.

PMID:
12910447
11.

Optimal extent of dopamine D2 receptor occupancy by antipsychotics for treatment of dopamine supersensitivity psychosis and late-onset psychosis.

Iyo M, Tadokoro S, Kanahara N, Hashimoto T, Niitsu T, Watanabe H, Hashimoto K.

J Clin Psychopharmacol. 2013 Jun;33(3):398-404. doi: 10.1097/JCP.0b013e31828ea95c. Review.

PMID:
23609386
12.

Dopamine- and serotonin-receptors in schizophrenia: results of imaging-studies and implications for pharmacotherapy in schizophrenia.

Kasper S, Tauscher J, Küfferle B, Barnas C, Pezawas L, Quiner S.

Eur Arch Psychiatry Clin Neurosci. 1999;249 Suppl 4:83-9. Review.

PMID:
10654113
13.

From dopamine to salience to psychosis--linking biology, pharmacology and phenomenology of psychosis.

Kapur S, Mizrahi R, Li M.

Schizophr Res. 2005 Nov 1;79(1):59-68. Review.

PMID:
16005191
14.
16.

Role of dopamine D(2) receptors for antipsychotic activity.

Ginovart N, Kapur S.

Handb Exp Pharmacol. 2012;(212):27-52. doi: 10.1007/978-3-642-25761-2_2. Review.

PMID:
23129327
17.

Mechanism of new antipsychotic medications: occupancy is not just antagonism.

Grunder G, Carlsson A, Wong DF.

Arch Gen Psychiatry. 2003 Oct;60(10):974-7. Review.

PMID:
14557141
18.

Receptor and transporter imaging studies in schizophrenia, depression, bulimia and Tourette's disorder--implications for psychopharmacology.

Kasper S, Tauscher J, Willeit M, Stamenkovic M, Neumeister A, Küfferle B, Barnas C, Stastny J, Praschak-Rieder N, Pezawas L, de Zwaan M, Quiner S, Pirker W, Asenbaum S, Podreka I, Brücke T.

World J Biol Psychiatry. 2002 Jul;3(3):133-46. Review.

PMID:
12478878
19.
20.

Antipsychotic drug mechanisms and neurotransmitter systems in schizophrenia.

Reynolds GP.

Acta Psychiatr Scand Suppl. 1994;380:36-40. Review.

PMID:
7914046

Supplemental Content

Support Center